BRC1.jpg
BRCA12Risks.png
BRCA1-2SecondCancerRisks-2.png
BRCA-management_from_family_history_not_enough.png
BRCA-associated_syndrome-01.png
BRCA-associated_syndrome-02.png

CANCER

GENETIC CANCER RISK

Female Breast

High Risk

Ovarian

High Risk

Male Breast

Elevated Risk

Pancreatic

Elevated Risk

Prostate

Elevated Risk

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR 

Female Breast

To age 50

28%-51%

1.9%

To age 70

46%-87%

7.1%

Second primary within 5 years of first breast cancer diagnosis

8.9%-20%

2%

Ovarian 

To age 50

8%-23%

0.2%

To age 70

39%-63%

0.7%

Ovarian cancer within 10 years of a breast cancer diagnosis

12.7%

<1.0%

Prostate

To age 70

Up to 16%

6.6%

Male Breast

To age 70

1.2%

<0.1%

Pancreatic

To age 80

Elevated Risk

1%

medical_managment-key.png

CANCER TYPE

GENETIC CANCER RISK

CANCER RISK

RISK FOR 

Female Breast

Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.

18 years

N/A

Clinical breast examination

25 years

Every 6 to 12 months

Breast MRI with contrast and/or mammography with consideration of tomosynthesis

Age 25 for MRI, or if MRI is unavailable, mammography with consideration of tomosynthesis. Age 30 for both MRI and mammography. Individualize to a younger age if a relative has been diagnosed younger than age 30.

Annually

Consider investigational screening studies within clinical trials.

Individualized

NA

Consider risk-reducing mastectomy.

Individualized

NA

Consider options for breast cancer risk-reduction agents (i.e. tamoxifen).

Individualized

NA

Ovarian 

Bilateral salpingo-oophorectomy, considering both the possible increased risk for serous uterine cancer and the possible advantages of hormone replacement therapy with estrogen only

35 to 40 years, upon completion of childbearing

NA

Consider transvaginal ultrasound and CA-125 measurement. Consider investigational screening studies within clinical trials.

30 to 35 years

Individualized

Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).

Individualized

I'm a paragraph.  

Prostate

Consider prostate cancer screening.

40 years

Individualized

Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be included as part of the risk and benefit discussion about prostate cancer screening.

NA

NA

Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be considered when choosing management options for men with a diagnosis of prostate cancer.

NA

NA

Male Breast

Breast self-examination

35 years

Monthly

Clinical breast examination

35 years

Annually

Pancreatic

For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.

Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family

Annually

Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.

Individualized

Individualized

For Patients With A Cancer Diagnosis

For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)

NA

NA

BRCA-medical_management-03.png
BRCA-medical_management-04.png
BRCA-medical_management-05.png
BRCA-medical_management-06.png
BRCA-unique_challenges-01.png
BRCA-unique_challenges-02.png
BRCA-unique_challenges-03.png